tiprankstipranks
Genomma Lab Internacional SAB de CV Class B (DE:GEKA)
FRANKFURT:GEKA
Germany Market
GEKA
Genomma Lab Internacional SAB de CV
RESEARCH TOOLSreports

Genomma Lab Internacional SAB de CV (GEKA) Earnings Dates, Call Summary & Reports

1 Followers

Earnings Data

Report Date
Jul 29, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.03
Last Year’s EPS
0.02
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Oct 23, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presents a company facing significant challenges, including a decline in sales due to external economic conditions and hyperinflationary effects. However, the management's focus on cost-saving measures and strategic investments in growth initiatives highlights a proactive approach to overcoming these hurdles. The resilience of the EBITDA margin and strong historical growth provide a foundation for potential recovery.
Company Guidance
During Genomma Lab's Third Quarter 2025 Earnings Conference Call, the company provided detailed guidance and metrics despite facing a challenging environment. Sales grew nearly 70% over recent years, with EBITDA more than doubling and free cash flow surging by 152%, while earnings per share increased by 46%. However, the third quarter saw a 2.9% like-for-like sales decline, translating to a 12.8% decrease in Mexican pesos due to hyperinflationary accounting effects in Argentina. The EBITDA margin remained stable at 23.7%, consistent with the 24% target, highlighting strong cost discipline. The company aims to achieve MXN 3 billion in savings by 2026, reallocating MXN 1.1 billion into growth strategies. This investment focuses on product innovation, go-to-market efforts, and expanding distribution, with expectations to generate up to MXN 5 billion in additional sales opportunities for 2026-2027. Despite these challenges, Genomma remains confident in returning to growth by the first half of 2026, maintaining a healthier margin and cash flow structure.
Strong Historical Growth
Genomma Lab has experienced significant growth over the past few years, with sales up nearly 70%, EBITDA more than doubling, free cash flow surging 152%, and EPS increasing by 46%.
Resilient EBITDA Margin
Despite top-line headwinds, the company's EBITDA margin remains strong at around 24%, demonstrating effective cost discipline and efficiency programs.
Strategic Productivity Measures
Genomma Lab identified MXN 3 billion in savings by 2026, which includes an additional MXN 1.1 billion in efficiencies to be reinvested in growth strategies.
Expansion in Traditional and E-commerce Channels
The company plans to expand its traditional channel coverage from 730,000 to over 1 million points of sales and grow e-commerce sales to MXN 2 billion by 2027.

Genomma Lab Internacional SAB de CV (DE:GEKA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

DE:GEKA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 29, 2026
2026 (Q2)
0.03 / -
0.017―――
Apr 23, 2026
2026 (Q1)
0.02 / 0.02
0.024-2.00% (>-0.01)―
Feb 26, 2026
2025 (Q4)
0.02 / 0.02
0.023-31.91% (>-0.01)―
Oct 23, 2025
2025 (Q3)
0.03 / 0.02
0.032-34.39% (-0.01)―
Jul 23, 2025
2025 (Q2)
0.03 / 0.02
0.031-44.44% (-0.01)―
Apr 30, 2025
2025 (Q1)
0.02 / 0.02
0.01838.89% (<+0.01)―
Feb 27, 2025
2024 (Q4)
0.03 / 0.02
-0.005527.27% (+0.03)―
Oct 23, 2024
2024 (Q3)
0.03 / 0.03
0.01970.10% (+0.01)―
Jul 24, 2024
2024 (Q2)
0.02 / 0.03
0.01958.29% (+0.01)―
Apr 24, 2024
2024 (Q1)
0.02 / 0.02
0.0175.57% (<+0.01)―
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:GEKA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 23, 2026
€0.89€0.89-0.56%
Feb 26, 2026
€0.83€0.82-1.20%
Oct 23, 2025
€0.76€0.760.00%
Jul 23, 2025
€0.88€0.90+2.15%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genomma Lab Internacional SAB de CV Class B (DE:GEKA) report earnings?
Genomma Lab Internacional SAB de CV Class B (DE:GEKA) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
    What is Genomma Lab Internacional SAB de CV Class B (DE:GEKA) earnings time?
    Genomma Lab Internacional SAB de CV Class B (DE:GEKA) earnings time is at Jul 29, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Genomma Lab Internacional SAB de CV Class B stock?
          The P/E ratio of Genomma Lab Internacional SAB de CV is N/A.
            What is DE:GEKA EPS forecast?
            DE:GEKA EPS forecast for the fiscal quarter 2026 (Q2) is 0.03.